Cardiovascular effects of erythropoietin and anemia correction.
about
Should hemoglobin be normalized in patients with chronic kidney disease?Carbamylated erythropoietin does not alleviate signs of dystrophy in mdx mice.Anemia in acute renal failure: role for erythropoiesis-stimulating proteins?Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin.High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetes.Usefulness of the blood hematocrit level to predict development of heart failure in a community.Etiology and management of anemia in patients with heart failure: how much iron is missing?Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States.The role of erythropoietin as an inhibitor of tissue ischemia.Primary hypertension and special aspects of hypertension in older children and adolescentsThe nonhematopoietic effects of erythropoietin in skin regeneration and repair: from basic research to clinical use.Hypertension in CKD Pregnancy: a Question of Cause and Effect (Cause or Effect? This Is the Question).The Pharmacology of Autonomic Failure: From Hypotension to Hypertension.Use of Aspirin in normalization of recombinant human erythropoietin-mediated hyper-reactivity of platelets in rats.Erythropoietin reduces the expression of myostatin in mdx dystrophic mice.Carbamylated Erythropoietin Outperforms Erythropoietin in the Treatment of AKI-on-CKD and Other AKI Models.Resistance to Recombinant Human Erythropoietin Therapy in a Rat Model of Chronic Kidney Disease Associated Anemia.Systemic and renal haemodynamic changes in renal schemia/reperfusion injury: impact of erythropoietin.Hemodynamic effects of anemia correction by recombinant human erythropoietin in predialysis patients with renal failure.A threshold trajectory was revealed by isolating the effects of hemoglobin rate of rise in anemia of chronic kidney disease.
P2860
Q34549905-6DDBF4F7-07DD-4D4F-8D97-DCE6BF1B6886Q34674989-057DB3D7-D690-407A-A072-7FD19D5544FCQ35206685-9599EE0F-455E-4C09-AA73-0306DB588B2BQ36677375-42267307-FBAF-4394-96EC-23DFDA00775FQ36799806-C936CB93-1A55-4B9D-AB44-83C7138D1038Q36873872-AE055442-A7E4-4EEE-8167-DBE62289CFB9Q37078810-59BAE879-A766-4207-8FA7-F0D42F0A07B7Q37123117-50FB3E2C-4275-496F-9393-65638A18D7C1Q37195742-E8FB48A1-AA77-4A27-809C-EB05059AD728Q37589007-96B7E8C4-AF38-4A96-BEBC-EFAFC2217515Q37995093-0EEA2376-551A-45C3-A77A-ECC0C94F38DEQ38806961-47FF6668-1466-492B-947E-F079681AE5D7Q39052115-6AFF33FD-5452-4FBA-9619-37FD6C2A3B06Q41229491-D53D06C4-6FCB-4265-95C0-2B93DA8A80DCQ42268979-C0E5D920-BB67-46A7-9D5E-9525E6643714Q42722918-4C69BEE8-34B5-4913-9C29-6F2FFB3CA7F3Q43064681-160ADB7B-3EDB-45C0-AC5E-C0462B6933CEQ46402870-3A417BFF-8898-4B58-AD61-6EA1FBCF1053Q53862120-3CFC1D23-49E9-4181-95C2-0B5541ECD9B9Q54961659-2607F5D9-802D-40EF-BDFC-C74A40D147F0
P2860
Cardiovascular effects of erythropoietin and anemia correction.
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Cardiovascular effects of erythropoietin and anemia correction.
@ast
Cardiovascular effects of erythropoietin and anemia correction.
@en
Cardiovascular effects of erythropoietin and anemia correction.
@nl
type
label
Cardiovascular effects of erythropoietin and anemia correction.
@ast
Cardiovascular effects of erythropoietin and anemia correction.
@en
Cardiovascular effects of erythropoietin and anemia correction.
@nl
prefLabel
Cardiovascular effects of erythropoietin and anemia correction.
@ast
Cardiovascular effects of erythropoietin and anemia correction.
@en
Cardiovascular effects of erythropoietin and anemia correction.
@nl
P1476
Cardiovascular effects of erythropoietin and anemia correction.
@en
P2093
P304
P356
10.1097/00041552-200109000-00013
P577
2001-09-01T00:00:00Z